Related Experiment Video
Updated: Jun 26, 2026
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
In vitro activity of cefiderocol against clinically relevant Gram-negative bacilli collected in China in 2023
Dandan Yin1, Fangfang Zhang2, Yan Guo1
1Huashan Hospital, Institute of Antibiotics, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China; Joint Laboratory of Hospital & Enterprise for Pathogen Diagnosis of Drug-resistant Bacterial Infections and Innovative Drug R&D, Shanghai, China.
Cefiderocol demonstrates strong in vitro effectiveness against common Gram-negative bacteria in China. Ongoing monitoring of resistance, especially in Enterobacter cloacae, is crucial for sustained efficacy.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Cefiderocol is a siderophore-conjugated cephalosporin with demonstrated in vitro activity against aerobic Gram-negative bacteria.
- This study evaluated the in vitro activity of cefiderocol against a large collection of clinical isolates from China.
Purpose of the Study:
- To assess the in vitro antimicrobial activity of cefiderocol against contemporary clinical isolates of Gram-negative bacteria in China.
- To compare cefiderocol's activity with other relevant antibiotics against resistant strains.
Main Methods:
- Antimicrobial susceptibility testing was performed using broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) guidelines.
- Testing included Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, and Burkholderia cepacia isolates collected in 2023.
Main Results:
- Cefiderocol exhibited potent activity against Enterobacterales, with susceptibility rates from 93.5% to 100%.
- High susceptibility rates were observed for Pseudomonas aeruginosa (99.7%), Acinetobacter baumannii (99.5%), and Stenotrophomonas maltophilia (98.4%).
- Cefiderocol demonstrated superior or similar activity compared to other agents against meropenem-resistant Gram-negative isolates.
Conclusions:
- Cefiderocol displays significant in vitro activity against a wide range of Gram-negative pathogens in China.
- Continuous surveillance of cefiderocol resistance patterns is necessary, particularly for Enterobacter cloacae, to guide clinical use and preserve effectiveness.
